Research is being conducted on the treatment of BRAFV600E mutated non-small cell lung cancer, with a focus on comparing immunotherapy and targeted therapy. The effectiveness of these approaches is being explored in various studies and guidelines are being developed by organizations such as NCCN, ASCO, IASLC, and ESMO. The optimal treatment strategy for this type of cancer remains a topic of discussion, with some studies suggesting that immunotherapy may be considered as a first-line treatment.